Recce Pharmaceuticals Ltd

ASX:RCE (Australia)  
A$ 0.69 (+5.38%) Apr 24
At Loss
P/B:
200.23
Market Cap:
A$ 132.57M ($ 86.24M)
Enterprise V:
A$ 128.76M ($ 83.76M)
Volume:
325.79K
Avg Vol (2M):
206.53K
Also Trade In:
Volume:
325.79K
At Loss
Avg Vol (2M):
206.53K

Business Description

Description
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.
Name Current Vs Industry Vs History
Cash-To-Debt 20.15
Equity-to-Asset 0.1
Debt-to-Equity 0.37
Debt-to-EBITDA -0.02
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -31
3-Year EPS without NRI Growth Rate -29.6
3-Year FCF Growth Rate -33.9

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.04
Quick Ratio 1.04
Cash Ratio 0.86

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.4
Shareholder Yield % -9.24
Name Current Vs Industry Vs History
ROE % -350.03
ROA % -318.28
ROIC % -1711.51
ROC (Joel Greenblatt) % -1903.56
ROCE % -3264600

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 200.23
EV-to-EBIT -11.83
EV-to-EBITDA -12.21
EV-to-Forward-EBITDA -2.02
EV-to-Forward-Revenue 16.8
EV-to-FCF -12.29
Earnings Yield (Greenblatt) % -8.45
FCF Yield % -6.9

Financials

ASX:RCE's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Recce Pharmaceuticals Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.064
Beta 0.3
Volatility % 51.2
14-Day RSI 79.1
14-Day ATR (A$) 0.034319
20-Day SMA (A$) 0.49975
12-1 Month Momentum % -27.41
52-Week Range (A$) 0.41 - 0.777246
Shares Outstanding (Mil) 203.95

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Recce Pharmaceuticals Ltd Filings

Filing Date Document Date Form
No Filing Data

Recce Pharmaceuticals Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Recce Pharmaceuticals Ltd Frequently Asked Questions

What is Recce Pharmaceuticals Ltd(ASX:RCE)'s stock price today?
The current price of ASX:RCE is A$0.69. The 52 week high of ASX:RCE is A$0.78 and 52 week low is A$0.41.
When is next earnings date of Recce Pharmaceuticals Ltd(ASX:RCE)?
The next earnings date of Recce Pharmaceuticals Ltd(ASX:RCE) is .
Does Recce Pharmaceuticals Ltd(ASX:RCE) pay dividends? If so, how much?
Recce Pharmaceuticals Ltd(ASX:RCE) does not pay dividend.

Press Release

Subject Date
No Press Release